NICE™

Diagnomics’s exclusive NIPT test, NICE® detects trisomy 21, 18, 13 and 4 sex chromosome aneuploidy in maternal blood. Using fetal cell-free DNA and NGS (next-generation sequencing), Diagnomics provides more accurate analysis as to NIPT service with 99% detection rate. Diagnomics is one of the first companies that includes trisomy 9, 16, 22 which detects chromosome aneuploidy. We are committed to provide further test such as amniocentesis only if the NICE®test result is positive. Upon request, test for AFP (alpha-fetoprotein) is available.

How is the NICE test different from other prenatal screening tests?

–There are a number of non-invasive prenatal birth tests on the market based on biochemical markers using maternal blood (including triple tests, quad tests, and integrated tests) but all have a false positive rate of 5% or more. Therefore, only 2 to 3 % of reported cases belong to the high risk group actually develop Down syndrome and the rest of the 98% are normal, even though they are diagnosed as belong to the high risk group. Therefore, 98% of pregnant women who are perfectly normal but with incorrect diagnosis of being high risk group are forced to go through invasive tests such as chorionic villus sampling or amniotic fluid test, which exposes them to the risk of side effects including miscarriage [1~2%]. The NICE® test is non-invasive prenatal test and has demonstrated excellent reliability of 99% or higher for the detection of chromosol banalities, particularly Down syndrome. The NICE® test has 0.1 % or less false positive rate in detecting these genetic defects in the fetus, significantly reducing the risks involved with chorionic villus sample or amniotic test.